MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 2, 2006--ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the recent publication of two clinical research papers that support the expansion of the clinical development of Ceflatonin(R) to include treatment of both newly diagnosed acute myeloid leukemia (AML) patients and those with advanced disease resistant to other therapies.
